Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma

Br J Dermatol. 2008 Feb;158(2):243-50. doi: 10.1111/j.1365-2133.2007.08310.x. Epub 2007 Nov 19.

Abstract

Background: The chromosome 9p21 and its CDKN locus, with the p16 tumour suppressor gene (CDKN2A), are recognized as the genomic regions involved in the pathogenesis of melanoma.

Objectives: To elucidate further the role of such regions during the different phases of melanocytic tumorigenesis.

Methods: Tissue sections from naevi, primary and metastatic melanomas were investigated by fluorescence in situ hybridization for allelic loss at the 9p21 chromosome and by immunochemistry for p16CDKN2A expression.

Results: Dysplastic naevi and primary or secondary melanomas were found to carry hemizygous deletions within the entire 9p21 region at similar frequencies (varying from 55% to 62%). Allelic deletion spanning the CDKN locus was observed at significantly increased rates moving from early (7%) to advanced (28%) primary melanomas and to secondary melanoma lesions (37%) (P=0.018). Also, inactivation of the p16 gene (CDKN2A) was absent in naevi and present at steadily increasing rates moving from primary melanomas (7% early lesions to 17% advanced lesions) to melanoma metastases (62%) (P=0.004).

Conclusions: Our findings indicate that, in a model of sequential accumulation of genetic alterations, 9p21 deletions may play a role in melanocytic transformation and tumour initiation whereas rearrangements at the CDKN locus, and p16 gene (CDKN2A) inactivation may contribute to tumour progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chromosomes, Human, Pair 9 / genetics*
  • Female
  • Genes, p16*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Italy
  • Loss of Heterozygosity
  • Male
  • Melanoma / genetics*
  • Middle Aged
  • Nevus, Pigmented / genetics*
  • Skin Neoplasms / genetics*